BEAM vs DNLI: stock comparison and AI forecast
Beam Therapeutics Inc. (BEAM) and Denali Therapeutics Inc. (DNLI) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BEAM Beam Therapeutics Inc.
- Price
- $25.87 -17.8% · 6M
- Market Cap
- $2.67B
- P/E Ratio
- 369.6x
- Size
- mid-cap
- AI Forecast
DNLI Denali Therapeutics Inc.
- Price
- $19.72 +0.1% · 6M
- Market Cap
- $3.15B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- DNLI is 1.2 times larger than BEAM by market capitalization ($3.15B against $2.67B).
- Over the last six months DNLI returned +0.1% and BEAM -17.8%.
- DNLI carries 0.36 times debt per unit of equity, against 0.33 times for BEAM.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BEAM | DNLI |
|---|---|---|
| Market Cap | $2.67B | $3.15B |
| P/E Ratio | 369.56x | – |
| P/B Ratio | 2.80x | 3.40x |
| EPS | $0.07 | $-1.82 |
| Book Value/Share | $9.22 | $5.80 |
| Revenue/Share | $1.42 | – |
| FCF/Share | $-3.86 | $-2.82 |
Profitability & Margins
| Metric | BEAM | DNLI |
|---|---|---|
| ROE | – | -33.9% |
| ROA | – | -25.0% |
| ROIC | -33.1% | -45.8% |
| Operating Margin | -267.7% | -2992.5% |
| Net Margin | – | -1768.6% |
| EBT Margin | -89.2% | -2992.5% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | BEAM | DNLI |
|---|---|---|
| Current Ratio | 13.00x | 6.21x |
| Quick Ratio | – | 5.94x |
| D/E Ratio | 0.33x | 0.36x |
| Financial Leverage | 1.33x | 1.36x |
| Interest Coverage | -54.5x | – |
| Working Capital | $985M | $496M |
Cash Flow
| Metric | BEAM | DNLI |
|---|---|---|
| Operating Cash Flow | -$389M | -$444M |
| Free Cash Flow | -$398M | -$450M |
| Capital Spending | -$10M | -$6M |
| FCF/Sales | -271.6% | – |
| CapEx/Sales | 6.5% | – |
Operational Efficiency
| Metric | BEAM | DNLI |
|---|---|---|
| Asset Turnover | 0.12x | – |
| Fixed Assets Turnover | 1.6x | – |
Income Statement
| Metric | BEAM | DNLI |
|---|---|---|
| Total Revenue | $147M | – |
| Operating Income | -$393M | -$532M |
| Net Income | – | -$314M |
| R&D Expense | $409M | $405M |
Dividend & Shareholder Information
| Metric | BEAM | DNLI |
|---|---|---|
| Shares Outstanding | 103M | 160M |
BEAM vs DNLI: stock comparison and AI forecast
Which is bigger, BEAM or DNLI?
DNLI is 1.2 times larger than BEAM by market capitalization ($3.15B against $2.67B).
Which stock performed better over the last six months, BEAM or DNLI?
Over the last six months DNLI returned +0.1% and BEAM -17.8%.
Which one does Intratio's AI model rank higher, BEAM or DNLI?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.